| Name | Halcinonide |
| Description | Halcinonide (Halciderm), a high-efficiency corticosteroid, is served as an anti-inflammatory agent used in topical preparations. |
| In vitro | After administering 0.1% Halcinonide cream for three days, the total number of peritoneal white blood cells in rats decreased from 270 million to 120.73 million. The same dosage of the drug, when applied to the surface of injured rat cecum for 3 and 7 days, significantly reduced the average adhesion scores, with the adhesion rates in the experimental and control groups being 43.3% and 100%, respectively. |
| In vivo | Halcinonide interacts with hormone receptors in the cytoplasm, eliciting anti-inflammatory effects. It is employed in the treatment of certain skin disorders. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (98.91 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 4 mg/mL (8.79 mM), Heating is recommended.
|
| Keywords | SQ18566 | SQ 18566 | Smoothened | Smo | Inhibitor | inhibit | Halcinonide | GlucocorticoidReceptor | Glucocorticoid Receptor |
| Inhibitors Related | Nimodipine | Betamethasone | Mifepristone | Prednisone | Prednisolone acetate | Dexamethasone acetate | Dexamethasone | Betamethasone dipropionate | Dexamethasone Phosphate disodium | Prednisone acetate | Desonide | Megestrol acetate |
| Related Compound Libraries | Nuclear Receptor Compound Library | Cysteine Covalent Library | Reprogramming Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Stem Cell Differentiation Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | NMPA-Approved Drug Library | Anti-Cancer Drug Library |
United States
